Neurocrine Biosciences Inc (NBIX)
Net profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 341,300 | 249,700 | 154,500 | 89,600 | 407,300 |
| Revenue | US$ in thousands | 2,355,100 | 1,883,200 | 1,411,600 | 1,107,700 | 994,700 |
| Net profit margin | 14.49% | 13.26% | 10.95% | 8.09% | 40.95% |
December 31, 2024 calculation
Net profit margin = Net income ÷ Revenue
= $341,300K ÷ $2,355,100K
= 14.49%
Net profit margin is a key financial ratio that reflects the percentage of revenue that translates into net income after all expenses have been accounted for. Neurocrine Biosciences Inc's net profit margin has shown fluctuations over the years, indicating changes in the company's profitability.
In December 31, 2020, Neurocrine Biosciences Inc had a robust net profit margin of 40.95%, demonstrating strong profitability relative to its revenue. However, by December 31, 2021, the net profit margin decreased significantly to 8.09%, signaling a decline in the company's ability to convert sales into profits efficiently.
Subsequently, the net profit margin improved to 10.95% by December 31, 2022, showing a recovery in profitability. This trend continued as of December 31, 2023, with the net profit margin further increasing to 13.26%, reflecting enhanced efficiency in cost management or revenue growth strategies.
By December 31, 2024, Neurocrine Biosciences Inc's net profit margin strengthened to 14.49%, indicating sustained profitability and potentially effective operational measures.
Overall, the fluctuation in Neurocrine Biosciences Inc's net profit margin over the years highlights the company's ability to manage costs, generate revenue, and ultimately enhance its bottom line performance.
Peer comparison
Dec 31, 2024